Mizuho Securities analyst Difei Yang maintained a Buy rating on Revance Therapeutics (RVNC) today and set a price target of $34. The company’s shares closed yesterday at $11.66, close to its 52-week low of $10.51.
Yang observed:
“We spoke to Revance CEO Summit (AIS) conference in New Orleans on 05/15. We believe DAXI will be especially well-positioned in a market that has strong potential to grow. With an innovative product (only long-duration toxin) and potential for premium pricing, we believe RVNC shares are attractive today relative to the growth opportunity. Limited credit is currently given to the company’s therapeutics pipeline and new potential collaboration deals could offer additional upside as well.”
According to TipRanks.com, Yang is a 5-star analyst with an average return of 11.1% and a 42.0% success rate. Yang covers the Healthcare sector, focusing on stocks such as Nightstar Therapeutics Limited, Xeris Pharmaceuticals Inc, and Alder Biopharmaceuticals.
Revance Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $34.75, a 198.0% upside from current levels. In a report issued on May 9, H.C. Wainwright also reiterated a Buy rating on the stock with a $23 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $32.45 and a one-year low of $10.51. Currently, Revance Therapeutics has an average volume of 384.2K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Revance Therapeutics, Inc. is a clinical stage biotechnology company. It is engaged in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic, and therapeutic applications.
